The announcement follows the first injection of embryonic stem cells into a patient in the US who is partially paralysed as a result of a spinal cord injury. Last October, biotechnology company, Geron, announced the start of the first clinical trial of embryonic stem cells with the hope of repairing damaged nerves.
Another US biotechnology firm, Advanced Cell Technology, has now been given approval for a second clinical trial involving the injection of thousands of embryonic stem cells into the eyes of a dozen adult patients with a juvenile form of macular degeneration.
Robert Lanza, the company's chief scientific officer, said that the first patient could receive the stem cell transplants early in the new year and although the trial is designed primarily to assess safety, the first signs of visual improvement may be apparent within weeks.
"Talking to the clinicians, we could see something in six weeks, that's when we think we may see some improvements. It really depends on individual patients but that's a reasonable time frame when something may start to happen," Dr Lanza said.
Embryonic stem cells, which are derived from IVF embryos left over from fertility treatment, have the ability to develop into any of the dozens of specialised cells of the body. Researchers believe they could revolutionise medicine because of their ability to repair damaged tissues and organs in situ without the need for whole-organ transplants.
However, "pro-life" groups such as the Roman Catholic Church are bitterly opposed to the practice which they say involves the deliberate destruction of potential human beings -- even if they are only three-day-old embryos.
Last week, a Glasgow man in his 60s with stroke damage to his brain became the world's first person to receive injections of stem cells derived from an aborted foetus.